Skip to main content

Memory Disorders Research

Alzheimer’s Disease


TRAILBLAZER-ALZ2

Investigator: Paul Schulz, MD

Purpose: Eli Lilly and Company/Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease.

Key Inclusion Criteria: 60-85 yrs with mild AD symptoms; ability to undergo PET scans; requires study partner.

Enrollment Status: Opening in near future

Contact Us: To learn more about this trial, please fill out this short online form »


The Oral Microbiome in Patients with Dementia

Investigator: Paul Schulz, MD, Cameron Jeter, MD

Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner.

Enrollment Status: Opening in near future

Contact Us: To learn more about this trial, please fill out this short online form »


Stem Cell Therapy for Early AD

Investigator: Paul Schulz, MD

Purpose: Stem Cell Therapy for Early AD

Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner

Enrollment Status: Opening in the near future

Contact Us: To learn more about this trial, please fill out this short online form »


Plasma Exchange for the Treatment of Early AD

Investigator: Paul Schulz, MD

Purpose: Plasma Exchange for the treatment of Early AD

Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner

Enrollment Status: Opening in near future

Contact Us: To learn more about this trial, please fill out this short online form »

Clinical Trials

Please fill out the fields to receive information about an ongoing UTHealth Neurosciences clinical trial.
  • This field is for validation purposes and should be left unchanged.